Watson Pharmaceuticals Incorporated (WPI) PT Lowered to $73.00 by Piper Jaffray (PJC

Equities research analysts at Piper Jaffray (NYSE: PJC) decreased their price target on shares of Watson Pharmaceuticals Incorporated (NYSE: WPI) to $73.00 in a research note issued to investors on Monday.Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Wednesday, January 18th. Analysts at Goldman Sachs (NYSE: GS) cut their EPS estimates on shares of Watson Pharmaceuticals Incorporated in a research note on Friday. They now have a “buy” rating and a $78.00 price target on the stock. Also, analysts at Jefferies Group (NYSE: JEF) reiterated a “hold” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday, December 20th. They now have a $70.00 price target on the stock.Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. It operates in three segments: Global Generics, Global Brands and Distribution. It operates in international markets, including Western Europe, Canada, Australasia, Asia, South America and South Africa with its commercial market being the United States of America. As of December 31, 2010, it marketed approximately 160 generic pharmaceutical product families and approximately 30 brand pharmaceutical product families in the United States, and distributed approximately 8,500 stock-keeping units (SKUs) through its Distribution Division. In January 2010, the Company acquired 64% of Eden Biopharm Group Limited (Eden). In May 2011, it acquired Specifar Pharmaceuticals S.A.Shares of Watson Pharmaceuticals Incorporated opened at 58.14 on Monday. Watson Pharmaceuticals Incorporated has a 52 week low of $53.46 and a 52 week high of $73.35. The stock’s 50-day moving average is $61.22 and its 200-day moving average is $65.50. The company has a market cap of $7.393 billion and a P/E ratio of 39.99.